Edition:
United States

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

13.99USD
12:48pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.99
Open
$14.02
Day's High
$14.05
Day's Low
$13.92
Volume
22,495
Avg. Vol
264,944
52-wk High
$17.98
52-wk Low
$11.47

Chart for

About

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium... (more)

Overall

Beta: 2.23
Market Cap(Mil.): $1,420.09
Shares Outstanding(Mil.): 101.51
Dividend: --
Yield (%): --

Financials

  INVA.OQ Industry Sector
P/E (TTM): 9.78 28.29 30.45
EPS (TTM): 1.43 -- --
ROI: 50.15 12.92 12.63
ROE: -- 14.94 14.82

BRIEF-Innoviva Names Geoffrey Hulme As Interim Principal Executive Officer

* INNOVIVA NAMES GEOFFREY HULME AS INTERIM PRINCIPAL EXECUTIVE OFFICER Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35

* Q1 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S

Apr 26 2018

Earnings vs. Estimates